CTLA4Ig combined with anti-LFA-1 prolongs cardiac allograft survival indefinitely.
CTLA4Ig and anti-LFA-1 are members of a new generation of immunomodulatory drugs which inhibit important signaling pathways in T cell activation. Both substances target molecules which have pivitol functions in the activation of CD4+ and CD8+ T cells and have been theorized to have an interdependent relationship. These drugs have been used independently in various treatment regimens and have shown great promise in prolonging the survival of allografts. In order to test whether these substances have synergistic or potentiating effects when combined, we performed mixed lymphocyte reactions, skin transplantation and vascularised heterotopic heart transplantation in the Balb/c (H-2(d)) to C3H/HeJ (H-2(k)) strain combination. When anti-LFA-1 and CTLA4Ig were combined at low doses, there was a substantial inhibition of lymphocyte proliferation. When each drug was used as a mono-therapy in skin graft recipients, there was no significant effect on median graft survival (anti-LFA-1, 15 days; CTLA4Ig, 16 days) when compared to untreated controls (13 days), whereas a combination of anti-LFA-1 and CTLA4Ig extended graft survival significantly to 32 days. Untreated vascularised heart grafts rejected at a median of 8 days, CTLA4Ig-treated mice rejected at a median time of 79 days and anti-LFA-1-treated mice rejected at 43 days (n = 9). When CTLA4Ig and anti-LFA-1 were combined, all animals had functioning heart grafts at 100 days after transplantation. Histological analysis of combined-therapy hearts showed no signs or only minor changes associated with chronic rejection. In conclusion, these results indicate a synergistic effect of combining anti-LFA-1 with CTLA4Ig in inhibiting lymphocyte proliferation and prolonging the survival of fully MHC-mismatched allografts.
Corbascio
Matthias
M
Department of Nephrology and Transplantation, Lund University, University Hospital, Malmo, Sweden. matthiasc@hotmail.com
Ekstrand
Helene
H
Osterholm
Cecilia
C
Qi
Zhongquan
Z
Simanaitis
Mecislovas
M
Larsen
Christian P
CP
Pearson
Thomas C
TC
Riesbeck
Kristian
K
Ekberg
Henrik
H
D000069594:Abatacept; D000818:Animals; D006085:Graft Survival; D016027:Heart Transplantation / Q000276:immunology*; D018796:Immunoconjugates / Q000627:therapeutic use*; D008213:Lymphocyte Activation; D007959:Lymphocyte Culture Test, Mixed; D016169:Lymphocyte Function-Associated Antigen-1 / Q000502:physiology*; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D016038:Skin Transplantation / Q000276:immunology; D014184:Transplantation, Homologous
D018796:Immunoconjugates; D016169:Lymphocyte Function-Associated Antigen-1; D000069594:Abatacept